Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design
Implicit in the drug-approval process is a host of decisions—target patient population, control group, primary endpoint, sample size, follow-up period, etc.—all of which determine the trade-off between Type I and Type II error. We explore the application of Bayesian decision analysis (BDA) to minimi...
Main Authors: | Isakov, L. (Author), Lo, A.W (Author), Montazerhodjat, V. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier Ltd
2019
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Stakeholder perspectives on adaptive clinical trials: a scoping review
by: Tina Madani Kia, et al.
Published: (2020-06-01) -
Adaptive designs for dose response studies
by: Chang, Yu-Hui Huang
Published: (2010) -
The Bayesian Design of Adaptive Clinical Trials
by: Alessandra Giovagnoli
Published: (2021-01-01) -
When to keep it simple – adaptive designs are not always useful
by: James M. S. Wason, et al.
Published: (2019-08-01) -
The changing perspective of clinical trial designs
by: Yamini Ajmera, et al.
Published: (2021-01-01)